<DOC>
	<DOCNO>NCT00873938</DOCNO>
	<brief_summary>With change malaria treatment policy use combination antimalaria therapy , envisage compliance combination therapy would less monotherapy use case management Ghana . This especially amodiaquine unpopular side-effects combination therapy single formulation ( fix dose ) . Compliance may enhance community supervision home visit combination antimalarial therapy case uncomplicated malaria . This study would assess compliance Artesunate-Amodiaquine therapy . It would also assess effect compliance artesunate-amodiaquine therapy clinical parasitological cure rate . This study target age group ten year , would complement child artesunate -amodiaquine efficacy study undertaken investigator child ten year Kintampo District time . The funding child study approve Gates Malaria Partnership . Findings study , involve age group would make available National Malaria Control Programme stakeholders practical information may beneficial implementing policy change process antimalarial monotherapy combination therapy .</brief_summary>
	<brief_title>Compliance Artesunate-Amodiaquine Therapy Uncomplicated Malaria Rural Ghana</brief_title>
	<detailed_description>Primary objective : • To determine compliance artesunate-amodiaquine therapy among patient diagnose acute uncomplicated malaria Kintampo District Hospital . Secondary objective : 1 . To determine patient compliance two drug ( artesunate amodiaquine ) 2 . To determine reason differential compliance either two drug ( artesunate amodiaquine ) . 3 . To determine patient perception acceptance artesunate-amodiaquine therapy acute uncomplicated malaria . 4 . To determine effect compliance artesunate-amodiaquine therapy clinical parasitological improvement acute uncomplicated malaria . Study design : The study pragmatic randomize control trial . Patients recruit base inclusion criterion state . Baseline clinical symptom malaria presence malaria parasite ( Plasmodium falciparum ) blood eligible patient report sick health facility would determine . Study patient would randomize one two group , intervention control group . Intervention : The intervention refers supervisory home visit train community volunteer ensure paticipants comply treatment artesunate-amodiaquine therapy . Supervisory home visit train community volunteer form major component Community Health Planning Services programme implement Ghana Health Service . The intervention group would supervise artesunate-amodiaquine therapy control group would supervise artesunate-amodiaquine therapy . The primary secondary outcome measure determine compare among intervention control group Primary outcome measure : The main outcome compliance artesunate-amodiaquine combination therapy . It define artesunate amodiaquine leave fourth day start treatment malaria episode . This would assess investigator direct observation blister package artesunate-Amodiaquine tablet . Secondary outcome measure : - Reasons non-compliance would determine response study participant . Care-takers child 18 year answer behalf child child 's assent . - Participants ' perception acceptance supervision : It would assess response give study participant indepth interview . - Parasite clearance rate day 14 28 i.e . proportion study participant group P. falciparum parasiteamia day 14 28 determine blood smear microscopy . - Clinical cure rate day 14 28 i.e . proportion study participant group symptom malaria day 14 28 determine structure questionnaire time .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Amodiaquine</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<criteria>Inclusion criterion : Male female patient age ten year report Kintampo district hospital . Diagnosed Plasmodium falciparum uncomplicated malaria . Axillary temperature ≥37.5oC le 40 oC history fever precede 24 hr . Ability tolerate oral therapy . Patient live locate Kintampo District . Consent patient and/or care giver ( case child ) Exclusion criterion : Pregnant woman . Children ten year ( cater child antimalarial efficacy study mention ) .</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2009</verification_date>
	<keyword>Artesunate-Amodiaquine</keyword>
	<keyword>Compliance</keyword>
	<keyword>Malaria</keyword>
</DOC>